210 East Grand Avenue
South San Francisco, CA 94080
United States
650 457 2700
https://www.allogene.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 359
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D. | Co-Founder & Exec. Chairman | 714.25k | N/A | 1949 |
Dr. David D. Chang M.D., Ph.D. | Co-Founder, Pres, CEO & Director | 1.1M | N/A | 1960 |
Mr. Joshua A. Kazam | Co-Founder & Director | 711k | N/A | 1977 |
Yinlin Chen | Sr. VP of Fin. | N/A | N/A | N/A |
Mr. Timothy L. Moore Ph.D. | Exec. VP & Chief Technical Officer | N/A | N/A | 1961 |
Mr. Earl M. Douglas Esq. | Gen. Counsel & Compliance Officer | N/A | N/A | 1963 |
Ms. Susan R. Lundeen | Chief People Officer | N/A | N/A | 1966 |
Ms. Christine Cassiano | Exec. VP, Chief Corp. Affairs & Brand Strategy Officer | N/A | N/A | N/A |
Dr. Zachary J. Roberts M.D., Ph.D. | Exec. VP of R&D and Chief Medical Officer | N/A | N/A | 1978 |
Mr. David M. Tanen J.D. | Sec. | N/A | N/A | 1971 |
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Allogene Therapeutics, Inc.’s ISS governance QualityScore as of 1 October 2023 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder rights: 8; Compensation: 10.